4.5 Article

Epilepsy imaging study guideline criteria: Commentary on diagnostic testing study guidelines and practice parameters

Journal

EPILEPSIA
Volume 52, Issue 9, Pages 1750-1756

Publisher

WILEY
DOI: 10.1111/j.1528-1167.2011.03155.x

Keywords

Epilepsy; Imaging; Guidelines

Funding

  1. Lundbeck Inc.
  2. King Pharmaceuticals
  3. PRA International, Eisai Inc.
  4. Marinus Pharmaceuticals, Inc.
  5. NIH [NINDS] [1R01NS44280-01]
  6. NIH NICHD [1P30HD40677-01]
  7. NCRR [1K12RR17613-01]
  8. NIMH [1 R01 MH065395-01A2]
  9. CDC-APTR [R-03]
  10. National Institute for Health Research [NF-SI-0509-10161] Funding Source: researchfish

Ask authors/readers for more resources

Recognition of limited economic resources, as well as potential adverse effects of over testing, has increased interest in evidence-based assessment of new medical technology. This creates a particular problem for evaluation and treatment of epilepsy, which are increasingly dependent on advanced imaging and electrophysiology, since there is a marked paucity of epilepsy diagnostic and prognostic studies that meet rigorous standards for evidence classification. The lack of high quality data reflects fundamental weaknesses in many imaging studies but also limitations in the assumptions underlying evidence classification schemes as they relate to epilepsy, and to the practicalities of conducting adequately powered studies of rapidly evolving technologies. We review the limitations of current guidelines and propose elements for imaging studies that can contribute meaningfully to the epilepsy literature.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available